State Of New Jersey Common Pension Fund D Reata Pharmaceuticals Inc Transaction History

State Of New Jersey Common Pension Fund D

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 02, 2023	BUY	$79.22 - $105.37 $2.11 Million - $2.8 Million	26,606 New	26,606 $2.71 Million
Q1 2022 May 03, 2022	SELL	$24.12 - $39.6 $754,811 - $1.24 Million	-31,294 Closed	0 $0
Q4 2021 Jan 31, 2022	BUY	$25.61 - $110.96 $141,111 - $611,389	5,510 Added 21.37%	31,294 $825,000
Q3 2021 Oct 27, 2021	SELL	$100.0 - $143.02 $420,400 - $601,256	-4,204 Reduced 14.02%	25,784 $2.59 Million
Q2 2021 Jul 23, 2021	BUY	$78.27 - $151.29 $790,370 - $1.53 Million	10,098 Added 50.77%	29,988 $4.24 Million
Q1 2021 Apr 27, 2021	BUY	$94.25 - $132.81 $91,893 - $129,489	975 Added 5.15%	19,890 $1.98 Million
Q4 2020 Feb 03, 2021	SELL	$102.03 - $184.62 $278,745 - $504,381	-2,732 Reduced 12.62%	18,915 $2.34 Million
Q3 2020 Oct 27, 2020	BUY	$93.53 - $163.34 $469,707 - $820,293	5,022 Added 30.21%	21,647 $2.11 Million
Q2 2020 Aug 04, 2020	BUY	$126.3 - $176.56 $271,671 - $379,780	2,151 Added 14.86%	16,625 $2.59 Million
Q4 2019 Jan 31, 2020	BUY	$74.57 - $217.92 $1.08 Million - $3.15 Million	14,474 New	14,474 $2.96 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of State Of New Jersey Common Pension Fund D, based on Form 13F filings with the SEC.

Stay updated on State Of New Jersey Common Pension Fund D with notifications on news.